Hematologic Oncology Update, Issue 3, 2016 (Video Program) - Video 3


Activity of FDA-approved (idelalisib) and investigational (copanlisib) PI3K inhibitors in indolent NHL
2:50 minutes.

Non-Hodgkin lymphoma (NHL), Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

Acute and chronic leukemias and myeloproliferative neoplasms

Multiple myeloma (MM)